Review





Similar Products

foxp3 fixation permeabilization buffer  (Thermo Fisher)
99
Thermo Fisher foxp3 fixation permeabilization buffer
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation Permeabilization Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation permeabilization buffer/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
foxp3 fixation permeabilization buffer  (Miltenyi Biotec)
99
Miltenyi Biotec foxp3 fixation permeabilization buffer
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation Permeabilization Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation permeabilization buffer/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
foxp3 fixation permeabilization buffer - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
foxp3 fixation/membrane-breaking working solution  (Thermo Fisher)
90
Thermo Fisher foxp3 fixation/membrane-breaking working solution
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation/Membrane Breaking Working Solution, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation/membrane-breaking working solution/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 fixation/membrane-breaking working solution - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 fixation/permeabilization solution  (Thermo Fisher)
90
Thermo Fisher foxp3 fixation/permeabilization solution
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation/Permeabilization Solution, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation/permeabilization solution/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 fixation/permeabilization solution - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 fixation buffer cat #005523  (Thermo Fisher)
90
Thermo Fisher foxp3 fixation buffer cat #005523
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation Buffer Cat #005523, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation buffer cat #005523/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 fixation buffer cat #005523 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 fixation/permeabilization concentrate and diluent  (Thermo Fisher)
90
Thermo Fisher foxp3 fixation/permeabilization concentrate and diluent
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation/Permeabilization Concentrate And Diluent, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation/permeabilization concentrate and diluent/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 fixation/permeabilization concentrate and diluent - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 fixation/permeabilization working solution  (Thermo Fisher)
90
Thermo Fisher foxp3 fixation/permeabilization working solution
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Fixation/Permeabilization Working Solution, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 fixation/permeabilization working solution/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 fixation/permeabilization working solution - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 transcription factor fixation/permeabilization kit  (Thermo Fisher)
90
Thermo Fisher foxp3 transcription factor fixation/permeabilization kit
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Transcription Factor Fixation/Permeabilization Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 transcription factor fixation/permeabilization kit/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 transcription factor fixation/permeabilization kit - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
foxp3 permeabilization/fixation kit  (Thermo Fisher)
90
Thermo Fisher foxp3 permeabilization/fixation kit
a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + <t>Foxp3</t> + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.
Foxp3 Permeabilization/Fixation Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foxp3 permeabilization/fixation kit/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
foxp3 permeabilization/fixation kit - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

Journal: bioRxiv

Article Title: Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumour cells

doi: 10.1101/2025.10.27.684825

Figure Lengend Snippet: a) Schematic of experiment. Mixed subcutaneous tumours were engrafted with BFP KRAS G12C cells plus 0.2% Luc-eGFP KRAS G12D cells. Mice were treated for six days with the RAS G12C(ON) inhibitor RMC-4998 (100 mg/kg; G12Ci / Ci) with or without the SHP2 inhibitor RMC-4550 (30 mg/kg; SHP2i / Si) or a-PD-1 (10 mg/kg). After treatment flow cytometry of tumours and tumour-draining lymph nodes (tdLN) was performed. For all subsequent plots, each dot represents one individual tumour; bar graphs indicate mean ± SD; One-way ANOVA Kruskal-Wallis test comparing vehicle to each of the treated conditions; only significant comparisons are shown. b) Fraction of KRAS G12C (left) and KRAS G12D (right) mutant tumour cells out of all life cells. c) Fraction of macrophages (MPs) out of all immune cells (CD45 + ). d) Macrophage polarisation: Fraction of Arg1 high /MHC-II low (left) and Arg1 low/MHC-ll high (right) MPs out of all MPs. e) Fraction of CD8 + T cells out of CD45 + cells. f) Fraction of NK cells out of CD45 + cells. g) CD8 + T cells to Treg (CD4 + Foxp3 + T cells) ratio by treatment group. h) Fraction of effector memory (Tem; CD62L - /CD44 + ; left) and TIM3 + /Lag3 + (right) CD8 + T cells out of CD45 + cells. i) In tumour draining lymph node (tdLN): fraction of Tem (CD62L - /CD44 + ) CD8 + T cells out of all CD8 + T cells.

Article Snippet: Subsequently, extracellular master mix, prepared with the antibodies listed in Table S6 diluted in Foxp3 Fixation/Permeabilization Buffer (Invitrogen, 00-5523-00), was added and samples were incubated for 30 min at 4°C.

Techniques: Flow Cytometry, Mutagenesis